Literature DB >> 19403557

Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress.

Yan Liu1, Yin Wang, Cindy Wu, Yang Liu, Pan Zheng.   

Abstract

The majority of the Lafora's disease (LD) is caused by defect in the EPM2A gene, including missense and nonsense mutations and deletions. These defects mainly occur in the carbohydrate-binding domain, and how these mutations cause neuronal defects is under active investigation. Here, we report that the mutant proteins encoded by all missense mutations and most deletions tested are unstable, insoluble and ubiquitinated, and are accumulated in aggresome-like structures. The effect of apparent 'gain-of-function' mutations can be corrected by co-transfection of wild-type EPM2A cDNA, which is consistent with the recessive nature of these mutations in LD patients. In a neuronal cell line, these mutant aggregates exacerbate endoplasm reticulum (ER) stress and make the cells susceptible to the apoptosis induced by ER stressor, thapsigargin. The chemical chaperon, 4-phenylbutyrate, increased the mutant solubility, reduced the ER stress and dulled the sensitivity of mutant neuronal cells to apoptosis induced by thapsigargin and the mutant laforin proteins. The increased sensitivity to ER stress-induced apoptosis may contribute to LD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403557      PMCID: PMC2701334          DOI: 10.1093/hmg/ddp196

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  37 in total

Review 1.  Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases.

Authors:  M Y Sherman; A L Goldberg
Journal:  Neuron       Date:  2001-01       Impact factor: 17.173

2.  Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy.

Authors:  B A Minassian; L Ianzano; M Meloche; E Andermann; G A Rouleau; A V Delgado-Escueta; S W Scherer
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

3.  A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.

Authors:  Jianyong Wang; Jeanne A Stuckey; Matthew J Wishart; Jack E Dixon
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

Review 4.  Advances in the genetics of progressive myoclonus epilepsy.

Authors:  A V Delgado-Escueta; S Ganesh; K Yamakawa
Journal:  Am J Med Genet       Date:  2001

Review 5.  Lafora's disease: towards a clinical, pathologic, and molecular synthesis.

Authors:  B A Minassian
Journal:  Pediatr Neurol       Date:  2001-07       Impact factor: 3.372

6.  Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.

Authors:  S Ganesh; K L Agarwala; K Ueda; T Akagi; K Shoda; T Usui; T Hashikawa; H Osada; A V Delgado-Escueta; K Yamakawa
Journal:  Hum Mol Genet       Date:  2000-09-22       Impact factor: 6.150

7.  Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms.

Authors:  Runhua Liu; Lizhong Wang; Chong Chen; Yan Liu; Penghui Zhou; Yin Wang; Xirui Wang; Julie Turnbull; Berge A Minassian; Yang Liu; Pan Zheng
Journal:  Mol Cell Biol       Date:  2008-09-29       Impact factor: 4.272

Review 8.  Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities.

Authors:  Inki Kim; Wenjie Xu; John C Reed
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

9.  Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy.

Authors:  Deepti Dubey; Subramaniam Ganesh
Journal:  Hum Mol Genet       Date:  2008-07-10       Impact factor: 6.150

10.  The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system.

Authors:  Punitee Garyali; Pratibha Siwach; Pankaj Kumar Singh; Rajat Puri; Shuchi Mittal; Sonali Sengupta; Rashmi Parihar; Subramaniam Ganesh
Journal:  Hum Mol Genet       Date:  2008-11-25       Impact factor: 6.150

View more
  15 in total

Review 1.  Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.

Authors:  Zhi-Hong Yu; Zhong-Yin Zhang
Journal:  Chem Rev       Date:  2017-05-25       Impact factor: 60.622

Review 2.  Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii.

Authors:  Matthew S Gentry; Carlos Romá-Mateo; Pascual Sanz
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

3.  Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.

Authors:  Yin Wang; Keli Ma; Peixiang Wang; Otto Baba; Helen Zhang; Jack M Parent; Pan Zheng; Yang Liu; Berge A Minassian; Yan Liu
Journal:  Mol Neurobiol       Date:  2013-04-02       Impact factor: 5.590

4.  Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.

Authors:  Arnaud Berthier; Miguel Payá; Ana M García-Cabrero; Maria Inmaculada Ballester; Miguel Heredia; José M Serratosa; Marina P Sánchez; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2015-01-28       Impact factor: 5.590

5.  Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes.

Authors:  Yin Wang; Allen T Bruce; Caixia Tu; Keli Ma; Li Zeng; Pan Zheng; Yang Liu; Yan Liu
Journal:  J Cell Sci       Date:  2011-11-01       Impact factor: 5.285

6.  Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease.

Authors:  Madushi Raththagala; M Kathryn Brewer; Matthew W Parker; Amanda R Sherwood; Brian K Wong; Simon Hsu; Travis M Bridges; Bradley C Paasch; Lance M Hellman; Satrio Husodo; David A Meekins; Adam O Taylor; Benjamin D Turner; Kyle D Auger; Vikas V Dukhande; Srinivas Chakravarthy; Pascual Sanz; Virgil L Woods; Sheng Li; Craig W Vander Kooi; Matthew S Gentry
Journal:  Mol Cell       Date:  2014-12-24       Impact factor: 17.970

7.  The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.

Authors:  Daniel Moreno; Mhairi C Towler; D Grahame Hardie; Erwin Knecht; Pascual Sanz
Journal:  Mol Biol Cell       Date:  2010-06-09       Impact factor: 4.138

8.  Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.

Authors:  Sudheendra N R Rao; Jaiprakash Sharma; Ranjan Maity; Nihar Ranjan Jana
Journal:  J Biol Chem       Date:  2009-11-05       Impact factor: 5.157

Review 9.  Unique carbohydrate binding platforms employed by the glucan phosphatases.

Authors:  Shane Emanuelle; M Kathryn Brewer; David A Meekins; Matthew S Gentry
Journal:  Cell Mol Life Sci       Date:  2016-05-04       Impact factor: 9.261

10.  Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.

Authors:  Irene López-González; Rosa Viana; Pascual Sanz; Isidre Ferrer
Journal:  Mol Neurobiol       Date:  2016-04-04       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.